New drug shrinks tumors in Hard-to-Treat bladder cancer

NCT ID NCT04995419

Completed Disease control Sponsor: Astellas Pharma China, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested enfortumab vedotin, a drug that delivers chemotherapy directly to cancer cells, in 40 Chinese patients with advanced bladder cancer that had worsened after standard treatments. The main goal was to see how many patients' tumors shrank. The trial also looked at how long the effect lasted and how safe the drug was. Results help determine if this drug is a good option for this patient group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin (PADCEV)
What this could lead to: If successful, this could provide a new treatment option for Chinese patients with advanced bladder cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 40 participants. The drug may cause side effects like nerve damage or skin reactions, and not all patients responded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma urinary bladder carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC UROTHELIAL CANCER

Contacts and locations

Locations

Site CN86001

Beijing, China
Site CN86002

Guangzhou, China
Site CN86003

Wuhan, China
Site CN86004

Shanghai, China
Site CN86006

Hangzhou, China
Site CN86007

Nanjing, China
Site CN86009

Changsha, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.